Lyell Immunopharma (LYEL) closed the sale of an additional $50M of shares of its common stock to investors from its July 2025 equity private placement of up to $100M, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel in patients with relapsed/refractory large B-cell lymphoma in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026. Most recently, she operated as an independent CFO and CBO consultant, providing strategic guidance to multiple life sciences organizations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma initiated with an Outperform at Citizens
- LYEL Earnings this Week: How Will it Perform?
- Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know
- Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target
- Lyell Immunopharma initiates patient dosing in PiNACLE-H2H Phase 3 trial